Quest PharmaTech Inc. (QPT.V)
| Previous Close | 0.0350 |
| Open | 0.0200 |
| Bid | 0.0250 x 0 |
| Ask | 0.0300 x 0 |
| Day's Range | 0.0200 - 0.0200 |
| 52 Week Range | 0.0200 - 0.1100 |
| Volume | |
| Avg. Volume | 7,159 |
| Market Cap | 3.383M |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jul 21, 2005 |
| 1y Target Est | N/A |
CNW GroupQuest Receives Cash Dividend Payment from OncoQuest
Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced that it has received a cash dividend payment from OncoQuest Inc. ("OncoQuest", one of Quest's investee companies) of approximately Cdn $685,000. Quest has a 42.5% ownership interest in OncoQuest. The dividend income will be used by Quest for general corporate purposes.
CNW GroupOregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits
Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced that it has received information that the Phase III clinical trial of oregovomab for the treatment of Ovarian Cancer, sponsored by CanariaBio Inc ("CAB"), has received recommendations from the Data Safety Monitoring Board (DSMB), an independent committee appointed by CAB to advise
CNW GroupQuest PharmaTech Provides Corporate Update
Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") wishes to provide an update to its June 2 and June 6, 2023 news releases announcing the entry into of a non-binding agreement in principle (the "Agreement in Principle") with OQP Bio Inc. ("OQP Bio") for the potential monetization of bonds held by Quest in OQP Bio.
